Innoviva (INVA) to Release Earnings on Thursday

Innoviva (NASDAQ:INVA - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Innoviva to post earnings of $0.34 per share and revenue of $92.59 million for the quarter.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share (EPS) for the quarter. The firm had revenue of $91.81 million during the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Price Performance

INVA traded up $0.37 during midday trading on Friday, reaching $17.92. 648,544 shares of the company's stock were exchanged, compared to its average volume of 540,793. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The business has a 50-day simple moving average of $18.04 and a two-hundred day simple moving average of $18.85. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of 25.97 and a beta of 0.55. Innoviva has a one year low of $14.32 and a one year high of $21.28.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Innoviva from a "buy" rating to a "hold" rating in a research note on Saturday, February 22nd.

Remove Ads

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.